Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.

Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM.

JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868.

2.

PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents.

Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen A, Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Baust K, Bautz A, Beck JD, Berger C, Binder H, Borgmann-Staudt A, Broer L, Cario H, Casagranda L, Clemens E, Deuster D, de Vries A, Dirksen U, Falck Winther J, Fosså S, Font-Gonzalez A, Grandage V, Haupt R, Hecker-Nolting S, Hjorth L, Kaiser M, Kenborg L, Kepak T, Kepáková K, Knudsen LE, Krawczuk-Rybak M, Kruseova J, Kuehni CE, Kunstreich M, Kuonen R, Lackner H, Leiper A, Loeffen EAH, Luks A, Modan-Moses D, Mulder R, Parfitt R, Paul NW, Ranft A, Ruud E, Schilling R, Spix C, Stefanowicz J, Strauβ G, Uitterlinden AG, van den Berg M, van der Kooi AL, van Dijk M, van Leeuwen F, Zolk O, Zöller D, Kaatsch P; PanCareLIFE consortium.

Eur J Cancer. 2018 Nov;103:227-237. doi: 10.1016/j.ejca.2018.08.007. Epub 2018 Sep 29.

PMID:
30273888
3.

Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol.

van der Kooi ALF, Clemens E, Broer L, Zolk O, Byrne J, Campbell H, van den Berg M, Berger C, Calaminus G, Dirksen U, Winther JF, Fosså SD, Grabow D, Haupt R, Kaiser M, Kepak T, Kremer L, Kruseova J, Modan-Moses D, Ranft A, Spix C, Kaatsch P, Laven JSE, van Dulmen-den Broeder E, Uitterlinden AG, van den Heuvel-Eibrink MM; PanCareLIFE Consortium.

BMC Cancer. 2018 Sep 26;18(1):930. doi: 10.1186/s12885-018-4834-3.

4.

The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.

Oosterom N, Berrevoets M, den Hoed MAH, Zolk O, Hoerning S, Pluijm SMF, Pieters R, de Jonge R, Tissing WJE, van den Heuvel-Eibrink MM, Heil SG.

Pharmacogenet Genomics. 2018 Oct;28(10):223-229. doi: 10.1097/FPC.0000000000000352.

PMID:
30222710
5.

The influence of genetic variation on late toxicities in childhood cancer survivors: A review.

Clemens E, van der Kooi ALF, Broer L, van Dulmen-den Broeder E, Visscher H, Kremer L, Tissing W, Loonen J, Ronckers CM, Pluijm SMF, Neggers SJCMM, Zolk O, Langer T, Zehnhoff-Dinnesen AA, Wilson CL, Hudson MM, Carleton B, Laven JSE, Uitterlinden AG, van den Heuvel-Eibrink MM.

Crit Rev Oncol Hematol. 2018 Jun;126:154-167. doi: 10.1016/j.critrevonc.2018.04.001. Epub 2018 Apr 12. Review.

6.

Prescribing of anticancer drugs in renal impairment: why can't we do better?

Abdel-Kahaar E, Zolk O.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Feb;391(2):107-109. doi: 10.1007/s00210-017-1461-5. Epub 2018 Jan 6. No abstract available.

PMID:
29307010
7.

Interventions for managing medication-related osteonecrosis of the jaw.

Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O.

Cochrane Database Syst Rev. 2017 Oct 6;10:CD012432. doi: 10.1002/14651858.CD012432.pub2. Review.

8.

[How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].

Hafner S, Haubensak S, Paul T, Zolk O.

Dtsch Med Wochenschr. 2016 Oct;141(21):e183-e202. Epub 2016 Oct 17. Review. German.

PMID:
27750332
9.

Pediatric Colorectal Carcinoma is Associated With Excellent Outcome in the Context of Cancer Predisposition Syndromes.

Weber ML, Schneider DT, Offenmüller S, Kaatsch P, Einsiedel HG, Benesch M, Claviez A, Ebinger M, Kramm C, Kratz C, Lawlor J, Leuschner I, Merkel S, Metzler M, Nustede R, Petsch S, Seeger KH, Schlegel PG, Suttorp M, Zolk O, Brecht IB.

Pediatr Blood Cancer. 2016 Apr;63(4):611-7. doi: 10.1002/pbc.25839. Epub 2015 Nov 17.

PMID:
26575411
10.

Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates.

Hacker K, Maas R, Kornhuber J, Fromm MF, Zolk O.

PLoS One. 2015 Sep 1;10(9):e0136451. doi: 10.1371/journal.pone.0136451. eCollection 2015.

11.

Water infusion versus air insufflation for colonoscopy.

Hafner S, Zolk K, Radaelli F, Otte J, Rabenstein T, Zolk O.

Cochrane Database Syst Rev. 2015 May 26;(5):CD009863. doi: 10.1002/14651858.CD009863.pub2. Review.

PMID:
26011829
12.

N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.

Müller F, Pontones CA, Renner B, Mieth M, Hoier E, Auge D, Maas R, Zolk O, Fromm MF.

Eur J Clin Pharmacol. 2015 Jan;71(1):85-94. doi: 10.1007/s00228-014-1770-2. Epub 2014 Oct 22.

PMID:
25552403
13.

Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics.

Bexten M, Oswald S, Grube M, Jia J, Graf T, Zimmermann U, Rodewald K, Zolk O, Schwantes U, Siegmund W, Keiser M.

Mol Pharm. 2015 Jan 5;12(1):171-8. doi: 10.1021/mp500532x. Epub 2014 Dec 10.

PMID:
25466967
14.

Accuracy and completeness of drug information in Wikipedia: a comparison with standard textbooks of pharmacology.

Kräenbring J, Monzon Penza T, Gutmann J, Muehlich S, Zolk O, Wojnowski L, Maas R, Engelhardt S, Sarikas A.

PLoS One. 2014 Sep 24;9(9):e106930. doi: 10.1371/journal.pone.0106930. eCollection 2014.

15.

The impact of hyoscine-N-butylbromide on adenoma detection during colonoscopy: meta-analysis of randomized, controlled studies.

Rondonotti E, Zolk O, Amato A, Paggi S, Baccarin A, Spinzi G, Radaelli F.

Gastrointest Endosc. 2014 Dec;80(6):1103-12.e2. doi: 10.1016/j.gie.2014.05.319. Epub 2014 Jul 19.

PMID:
25053528
16.

Focused screening of a panel of cancer-related genetic polymorphisms reveals new susceptibility loci for pediatric acute lymphoblastic leukemia.

Offenmüller S, Ravindranath Y, Goyette G, Kanakapalli D, Miller KS, Brecht IB, Zolk O.

Pediatr Blood Cancer. 2014 Aug;61(8):1411-5. doi: 10.1002/pbc.25011. Epub 2014 Mar 6.

17.

Alanine-glyoxylate aminotransferase 2 (AGXT2) polymorphisms have considerable impact on methylarginine and β-aminoisobutyrate metabolism in healthy volunteers.

Kittel A, Müller F, König J, Mieth M, Sticht H, Zolk O, Kralj A, Heinrich MR, Fromm MF, Maas R.

PLoS One. 2014 Feb 24;9(2):e88544. doi: 10.1371/journal.pone.0088544. eCollection 2014.

18.

Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).

Strobel J, Müller F, Zolk O, Endreß B, König J, Fromm MF, Maas R.

Amino Acids. 2013 Oct;45(4):989-1002. doi: 10.1007/s00726-013-1556-3. Epub 2013 Jul 18.

PMID:
23864433
19.

Understanding platinum-induced ototoxicity.

Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O.

Trends Pharmacol Sci. 2013 Aug;34(8):458-69. doi: 10.1016/j.tips.2013.05.006. Epub 2013 Jun 13. Review.

PMID:
23769626
20.

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.

Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Möricke A, Stanulla M, Schrappe M, Langer T.

Blood. 2013 Jun 27;121(26):5145-53. doi: 10.1182/blood-2013-01-480335. Epub 2013 May 7.

21.

Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.

Schnepf R, Zolk O.

Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):287-306. doi: 10.1517/17425255.2013.742063. Epub 2013 Jan 7. Review.

PMID:
23289909
22.

Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms.

Zolk O, Schnepf R, Muschler M, Fromm MF, Wendler O, Traxdorf M, Iro H, Zenk J.

Am J Pathol. 2013 Jan;182(1):234-43. doi: 10.1016/j.ajpath.2012.09.008. Epub 2012 Nov 6.

PMID:
23137910
23.

Warm water infusion colonoscopy: a review and meta-analysis.

Rabenstein T, Radaelli F, Zolk O.

Endoscopy. 2012 Oct;44(10):940-51. doi: 10.1055/s-0032-1310157. Epub 2012 Sep 17. Review.

PMID:
22987214
24.

Personalizing antiplatelet therapy with clopidogrel.

Trenk D, Zolk O, Fromm MF, Neumann FJ, Hochholzer W.

Clin Pharmacol Ther. 2012 Oct;92(4):476-85. doi: 10.1038/clpt.2012.133. Epub 2012 Sep 5. Review.

PMID:
22948893
25.

Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians.

Zolk O, Ott C, Fromm MF, Schmieder RE.

J Clin Hypertens (Greenwich). 2012 May;14(5):293-8. doi: 10.1111/j.1751-7176.2012.00618.x. Epub 2012 Apr 9.

26.

Drug transporter regulation in tumors by DNA methylation.

Zolk O, Fromm MF.

Genome Med. 2012 Jan 31;4(1):10. doi: 10.1186/gm309.

27.

Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization.

Solbach TF, Grube M, Fromm MF, Zolk O.

J Cardiovasc Pharmacol. 2011 Oct;58(4):409-17. doi: 10.1097/FJC.0b013e3182270783.

PMID:
21697722
28.

Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Neumann FJ.

Circ Cardiovasc Genet. 2011 Aug 1;4(4):429-36. doi: 10.1161/CIRCGENETICS.111.960112. Epub 2011 Jun 17.

PMID:
21685174
29.

Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.

Müller F, König J, Glaeser H, Schmidt I, Zolk O, Fromm MF, Maas R.

Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8. doi: 10.1128/AAC.01835-10. Epub 2011 Apr 25.

30.

Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions.

Zolk O, Fromm MF.

Clin Pharmacol Ther. 2011 Jun;89(6):798-805. doi: 10.1038/clpt.2010.354. Epub 2011 Apr 6. Review.

PMID:
21471963
31.

Disposition of metformin: variability due to polymorphisms of organic cation transporters.

Zolk O.

Ann Med. 2012 Mar;44(2):119-29. doi: 10.3109/07853890.2010.549144. Epub 2011 Mar 3. Review.

PMID:
21366511
32.

[Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology].

Rabenstein T, Fromm MF, Zolk O.

Z Gastroenterol. 2011 Feb;49(2):211-24. doi: 10.1055/s-0029-1245705. Epub 2011 Jan 11. Review. German.

PMID:
21225568
33.

Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.

König J, Zolk O, Singer K, Hoffmann C, Fromm MF.

Br J Pharmacol. 2011 Jun;163(3):546-55. doi: 10.1111/j.1476-5381.2010.01052.x.

34.

Drug transport by breast cancer resistance protein.

Poguntke M, Hazai E, Fromm MF, Zolk O.

Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1363-84. doi: 10.1517/17425255.2010.519700. Epub 2010 Sep 27.

PMID:
20873966
35.

Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.

Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, Sparreboom A.

Clin Cancer Res. 2010 Aug 15;16(16):4198-206. doi: 10.1158/1078-0432.CCR-10-0949. Epub 2010 Jul 2.

36.

The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost.

Kraft ME, Glaeser H, Mandery K, König J, Auge D, Fromm MF, Schlötzer-Schrehardt U, Welge-Lüssen U, Kruse FE, Zolk O.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. doi: 10.1167/iovs.09-4290. Epub 2009 Dec 17.

PMID:
20019365
37.

Gender is an important determinant of the disposition of the loop diuretic torasemide.

Werner U, Werner D, Heinbüchner S, Graf B, Ince H, Kische S, Thürmann P, König J, Fromm MF, Zolk O.

J Clin Pharmacol. 2010 Feb;50(2):160-8. doi: 10.1177/0091270009337514. Epub 2009 Nov 23.

PMID:
19934028
38.

Current understanding of the pharmacogenomics of metformin.

Zolk O.

Clin Pharmacol Ther. 2009 Dec;86(6):595-8. doi: 10.1038/clpt.2009.144.

PMID:
19915604
39.

Functionalized silicon quantum dots tailored for targeted siRNA delivery.

Klein S, Zolk O, Fromm MF, Schrödl F, Neuhuber W, Kryschi C.

Biochem Biophys Res Commun. 2009 Sep 11;387(1):164-8. doi: 10.1016/j.bbrc.2009.06.144. Epub 2009 Jul 2.

PMID:
19576864
40.

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M.

Clin Pharmacol Ther. 2009 Aug;86(2):197-203. doi: 10.1038/clpt.2009.79. Epub 2009 May 27.

PMID:
19474787
41.

Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser.

Zolk O, Solbach TF, König J, Fromm MF.

Drug Metab Dispos. 2009 Jun;37(6):1312-8. doi: 10.1124/dmd.108.023762. Epub 2009 Feb 27.

PMID:
19251820
42.

Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?

Hinz B, Renner B, Cheremina O, Besz D, Zolk O, Brune K.

Ann Rheum Dis. 2009 Feb;68(2):289-91. doi: 10.1136/ard.2008.092536. No abstract available.

PMID:
19139209
43.

Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2).

Zolk O, Solbach TF, König J, Fromm MF.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):337-48. doi: 10.1007/s00210-008-0369-5. Epub 2008 Nov 11.

PMID:
19002438
44.

Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure.

Zolk O, Solbach TF, Eschenhagen T, Weidemann A, Fromm MF.

Biochem Biophys Res Commun. 2008 Nov 14;376(2):315-20. doi: 10.1016/j.bbrc.2008.08.152. Epub 2008 Sep 7.

PMID:
18782560
45.

Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.

Werner D, Werner U, Meybaum A, Schmidt B, Umbreen S, Grosch A, Lestin HG, Graf B, Zolk O, Fromm MF.

Clin Pharmacokinet. 2008;47(5):323-32.

PMID:
18399713
46.

ATP-binding cassette transporters in human heart failure.

Solbach TF, Paulus B, Weyand M, Eschenhagen T, Zolk O, Fromm MF.

Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43. doi: 10.1007/s00210-008-0279-6. Epub 2008 Apr 8.

PMID:
18392808
47.

Functionalization of carbon nanotubes enables non-covalent binding and intracellular delivery of small interfering RNA for efficient knock-down of genes.

Krajcik R, Jung A, Hirsch A, Neuhuber W, Zolk O.

Biochem Biophys Res Commun. 2008 May 2;369(2):595-602. doi: 10.1016/j.bbrc.2008.02.072. Epub 2008 Feb 25.

PMID:
18298946
48.

Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic.

Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, Brune K.

FASEB J. 2007 Aug;21(10):2343-51. Epub 2007 Apr 13.

PMID:
17435173
49.

MDR1 genotype-dependent regulation of the aldosterone system in humans.

Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE.

Pharmacogenet Genomics. 2007 Feb;17(2):137-44.

PMID:
17301693
50.

Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition.

Doll D, Sarikas A, Krajcik R, Zolk O.

Biochem Biophys Res Commun. 2007 Feb 9;353(2):436-42. Epub 2006 Dec 12.

PMID:
17174276

Supplemental Content

Support Center